This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Ken Herrmann, M.D.
Chair, Department of Nuclear Medicine at Universitätsklinikum Essen
Speaker

Profile

Prof. Dr Herrmann is Professor of Nuclear Medicine at the Universitätsklinikum Essen, Essen, Germany and until recently acted as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), Los Angeles, California, USA.

In 2011, he completed his residency in nuclear medicine at Klinikum rechts der Isar, Technische Universität München, Munich, Germany, focusing on his research entitled “In Vivo Proliferation Imaging with 3´deoxy-3´-[18F]Fluorothymidine PET in Oncology”. Following this, Prof. Dr Herrmann then went onto complete a fellowship at Hokkaido University, Hokkaido, Japan, and received an executive MBA degree from the University of Zürich, Zürich, Switzerland. From 2012 to 2016, he served as Vice Chair of the Department of Nuclear Medicine at Universitätsklinikum Würzburg, Würzburg, Germany. He served as Chair of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee from 2020-2023.

Presently, he is the Section Editor of The Journal of Nuclear Medicine and of Cancer Imaging. He has also authored more 600 peer-reviewed articles.

Agenda Sessions

  • Next Wave of Radionuclide Theranostics

    8:30am